Published clinical research also describes Retatrutide as a triple-hormone-receptor agonist
If you have a background of specific health conditions, such as pancreatic inflammation, diabetic retinopathy, thyroid tumors, multiple endocrine neoplasia type 2, Type 1 diabetes, diabetic ketoacidosis, or kidney or liver disease, Ozempic may not be recommended for you
Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance
Clinical Obesity Journal
Most recently, in April 2023, Galderma received FDA approval for Sculptra to correct fine lines and wrinkles in the cheek area, with clinical efficacy data showing 96% improvement at three months and 94% improvement sustained at two years
This outcome positions retatrutide as a highly effective candidate, potentially more so than current treatments like semaglutide (Wegovy) and tirzepatide (Zepbound)